Preoperative Chemoradiation With Cetuximab, Irinotecan, and Capecitabine in Patients With Locally Advanced Resectable Rectal Cancer: A Multicenter Phase II Study

Article ID	Journal	Published Year	Pages	File Type
8228889	International Journal of Radiation OncologyBiologyPhysics	2011	7 Pages	PDF

Abstract

Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine was active and well tolerated. KRAS mutation status was not a predictive factor for pathologic response in this study.

Keywords

Irinotecan Cetuximab Rectal cancer Preoperative chemoradiotherapy Capecitabine

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Preoperative Chemoradiation With Cetuximab, Irinotecan, and Capecitabine in Patients With Locally Advanced Resectable Rectal Cancer: A Multicenter Phase II Study

Authors

Sun Young M.D., Yong Sang M.D., Dae Yong M.D., Ph.D., Tae Won M.D., Ph.D., Jee Hyun M.D., Ph.D., Seok Ah M.D., Ph.D., Keun Seok M.D., Tak M.D., Seung-Yong M.D., Ph.D., Hyo Seong M.D., Ph.D., Seok-Byung M.D., Ph.D., Hee Jin M.D., Ph.D., Kyung Hae M.D.,